|1.||Bonhaus, Douglas W: 2 articles (02/2010 - 10/2007)|
|2.||Davis, Robert E: 2 articles (02/2010 - 06/2008)|
|3.||Schiffer, Hans H: 1 article (02/2010)|
|4.||Burstein, Ethan S: 1 article (02/2010)|
|5.||Ott, Thomas R: 1 article (02/2010)|
|6.||McFarland, Krista: 1 article (02/2010)|
|7.||Bradley, Stefania Risso: 1 article (02/2010)|
|8.||Bajpai, Abhishek: 1 article (02/2010)|
|9.||Ohrmund, Linda: 1 article (02/2010)|
|10.||Spalding, Tracy A: 1 article (02/2010)|
|1.||Schizophrenia (Dementia Praecox)
02/01/2010 - "Therefore, AC-260584 may serve as a lead compound in the development of M(1) selective drugs for the treatment of cognitive impairment associated with schizophrenia and Alzheimer's disease."
10/31/2007 - "Therefore, AC260584, as well as other muscarinic M1 receptor agonists, may be a valuable target for the development of drugs which can improve the cognitive deficits in schizophrenia and perhaps other neuropsychiatric disorders, as well."
06/01/2008 - "In contrast to haloperidol, AC-260584 did not produce catalepsy. "
06/01/2008 - "AC-260584 was evaluated in animal models: antipsychotic-like effects were tested by the ability to reduce amphetamine- and MK-801-induced hyperactivity and apomorphine-induced climbing; catalepsy was assessed by measuring step-down latency; spatial memory was tested by using the Morris water maze. "
|3.||Alzheimer Disease (Alzheimer's Disease)
|1.||Muscarinic M1 Receptor